Literature DB >> 9973252

Down-regulation of liver JAK2-STAT5b signaling by the female plasma pattern of continuous growth hormone stimulation.

C A Gebert1, S H Park, D J Waxman.   

Abstract

The suppression of male-specific, GH pulse-induced, liver transcription in adult female rats has been linked to the down-regulation of STAT5b activation by the female plasma pattern of near-continuous GH exposure. The mechanism underlying this down-regulation was studied in the rat liver cell line CWSV-1, where continuous GH suppressed the level of activated (tyrosine- phosphorylated) STAT5b to approximately 10-20% of the maximal GH pulse-induced STAT5b signal within 3 h. In contrast to the robust JAK2 kinase-dependent STAT5b activation loop that is established by a GH pulse, JAK2 kinase signaling to individual STAT5b molecules was found to be short lived in cells treated with GH continuously. Moreover, maintenance of the low-level STAT5b signal required ongoing protein synthesis and persisted for at least 7 days provided that GH was present in the culture continuously. Increased STAT5b DNA-binding activity was observed in cells treated with the proteasome inhibitor MG132, suggesting that at least one component of the GH receptor (GHR)-JAK2-STAT5b signaling pathway becomes labile in response to continuous GH treatment. The phosphotyrosine phosphatase inhibitor pervanadate fully reversed the down-regulation of STAT5b DNA-binding activity in continuous GH-treated cells by a mechanism that involves both increased STAT5b activation and decreased STAT5b dephosphorylation. Moreover, the requirement for ongoing GH stimulation and active protein synthesis to maintain STAT5b activity in continuous GH-treated cells were both eliminated by pervanadate treatment, suggesting that phosphotyrosine dephosphorylation may be an obligatory first step in the internalization/degradation pathway for the GHR-JAK2 complex. Finally, the sustaining effect of the serine kinase inhibitor H7 on GH pulse-induced JAK2 signaling to STAT5b was not observed in continuous GH-treated cells. These findings suggest a model where continuous GH exposure of liver cells down-regulates the STAT5b pathway by a mechanism that involves enhanced dephosphorylation of both STAT5b and GHR-JAK2, with the latter step leading to increased internalization/degradation of the re-ceptor-kinase complex.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973252     DOI: 10.1210/mend.13.2.0238

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  14 in total

Review 1.  Growth hormone: new ideas, recurring themes.

Authors:  E O Reiter
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

2.  Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-dependent gene regulation in male and female mouse liver.

Authors:  Aarathi Sugathan; David J Waxman
Journal:  Mol Cell Biol       Date:  2013-07-08       Impact factor: 4.272

Review 3.  Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Growth Horm IGF Res       Date:  2014-12-20       Impact factor: 2.372

4.  The decrease in mature myostatin protein in male skeletal muscle is developmentally regulated by growth hormone.

Authors:  Jenny M Oldham; Claire C Osepchook; Ferenc Jeanplong; Shelley J Falconer; Kenneth G Matthews; John V Conaglen; David F Gerrard; Heather K Smith; Richard J Wilkins; James J Bass; Christopher D McMahon
Journal:  J Physiol       Date:  2008-12-01       Impact factor: 5.182

5.  Transgenic mice showing inflammation-inducible overexpression of granulocyte macrophage colony-stimulating factor.

Authors:  B Burke; A Pridmore; N Harraghy; A Collick; J Brown; T Mitchell
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

6.  The effect of different patterns of growth hormone administration on the IGF axis and somatic and skeletal growth of the dwarf rat.

Authors:  Melissa Westwood; Arfa R Maqsood; Mattea Solomon; Andrew J Whatmore; Julian R E Davis; Robert C Baxter; Evelien F Gevers; Iain C A F Robinson; Peter E Clayton
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10-27       Impact factor: 4.310

7.  Dynamic in vivo binding of STAT5 to growth hormone-regulated genes in intact rat liver. Sex-specific binding at low- but not high-affinity STAT5 sites.

Authors:  Ekaterina V Laz; Aarathi Sugathan; David J Waxman
Journal:  Mol Endocrinol       Date:  2009-05-07

Review 8.  Sex differences in the expression of hepatic drug metabolizing enzymes.

Authors:  David J Waxman; Minita G Holloway
Journal:  Mol Pharmacol       Date:  2009-05-29       Impact factor: 4.436

9.  Effects of growth hormone deficiency and rhGH replacement therapy on the 6beta-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children.

Authors:  Blanca Sinués; Esteban Mayayo; Ana Fanlo; Esteban Mayayo; María L Bernal; Pilar Bocos; Elena Bello; Jose I Labarta; Angel Ferrández-Longás
Journal:  Eur J Clin Pharmacol       Date:  2004-09-07       Impact factor: 2.953

10.  Male-specific hepatic Bcl6: growth hormone-induced block of transcription elongation in females and binding to target genes inversely coordinated with STAT5.

Authors:  Rosana D Meyer; Ekaterina V Laz; Ting Su; David J Waxman
Journal:  Mol Endocrinol       Date:  2009-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.